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ABSTRACT  
Background: Extracellular matrix (ECM) plays a crucial role in tumour behaviour. 
Prolyl-4-hydroxlase-A2 (P4HA2) is a key enzyme in ECM remodelling. This study aims to 
evaluate the prognostic significance of P4HA2 in breast ductal carcinoma in situ (DCIS).  
Methods: P4HA2 expression was assessed immunohistochemically in malignant cells and 
surrounding stroma of a large DCIS cohort comprising 481 pure DCIS and 196 mixed 
DCIS and invasive carcinomas. Outcome analysis was evaluated using local recurrence 
free interval (LRFI).  
Results: High P4HA2 expression was detected in malignant cells of half of pure DCIS 
whereas its expression in stroma was seen in 25% of cases. Higher P4HA2 expression 
was observed in mixed DCIS cases compared to pure DCIS both in tumour cells and in 
stroma. High P4HA2 was associated with features of high risk DCIS including younger 
age, higher grade, comedo necrosis, triple negative and HER2-positive phenotypes. 
Interaction between P4HA2 and radiotherapy was also observed regarding the outcome. 
High P4HA2 expression was an independent prognostic factor in predicting shorter LRFI. 
Conclusion: P4HA2 plays a role in DCIS progression and can potentially be used to 
predict DCIS outcome. Incorporation of P4HA2 with other clinicopathological parameters 
could refine DCIS risk stratification that can potentially guide management decisions. 
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INTRODUCTION  
Currently, determination of behaviour and proper management of DCIS depends on 
conventional clinicopathological parameters including patient age, nuclear grade, mode 
of disease presentation either symptomatic or screen detected, tumour size and 
presence of comedo type necrosis 1,2. Despite the prognostic value of these factors, they 
remain insufficient to define risk of progression precisely. Moreover, these parameters 
classify more than 50% of DCIS in the high-risk group, however the recurrence rate is 
currently around 15% with half of these being invasive 3. Therefore, a considerable 
percentage of DCIS patients are either over- or under-treated 4. Molecular 
characterisation based on hormonal receptors and HER2 status in addition to recently 
described multigene assays, such as Oncotype DX DCIS score, have shown promising 
results to refine DCIS prognostic classification but the value of their application in 
routine practice remains unclear 5-9. 
The role of the DCIS microenvironment and the crosstalk between intraductal malignant 
epithelial cells and the various components of the extra-ductal structures in the 
progression of DCIS to invasive disease is undeniable 10-14. However, previous studies 
have indicated that the precise role of proteolytic enzymes in the extracellular matrix 
(ECM), such as matrix metalloproteinases (MMPs), in predicting risk of development of 
local recurrence is unreliable and trials for blocking these enzymes to limit tumour 
progression showed disappointing results 15,16.  
Collagen is the main constituent of ECM and usually forms a network around tumour 
cells 17. Collagen biosynthesis is a multistep process with several post-translational 
modifications. Prolyl-4-hydroxylases catalyse the formation of 4-hydroxyproline, which is 
essential for collagen triple helix formation and fibre stabilisation 18. Increased P4HA2 
expression has been detected in many solid tumours, including oral cavity squamous cell 
carcinoma 19, papillary thyroid cancer 20, and invasive breast carcinoma (IBC) 21. 
Interestingly, P4HA2 is differentially expressed between normal breast tissue and IBC 
22,23. However, to the best of our knowledge, no previous study has addressed the role of 
P4HA2 in DCIS progression and its prognostic impact. In this study, we aimed to assess 
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the expression of P4HA2 in a large cohort of DCIS to evaluate its clinicopathological and 
prognostic significance.  
MATERIAL AND METHODS 
Study Cohort  
This study was carried out on a consecutive series of 776 primary pure DCIS cases 
diagnosed between 1990 to 2012 at Nottingham City Hospital, Nottingham, United 
Kingdom (UK). Supplementary Table 1 summarises the clinicopathological parameters of 
the study cohort. A series of 239 cases diagnosed as synchronous DCIS and IBC (DCIS-
mixed) was also collected as a comparison set. The latter was selected with 
clinicopathological features comparable to the pure cohort to avoid any selection bias 
(Supplementary Table 1). Patients’ demographic data, histopathological parameters, 
management including post-operative radiotherapy (RT) and development of local 
recurrence were collected. Local recurrence free interval (LRFI) was defined as the time 
(in months) between 6 months after the first DCIS surgery and occurrence of ipsilateral 
local recurrence (either as DCIS or IBC with or without ipsilateral nodal metastasis). 
Cases that underwent completion re-excision surgery within the first 6 months of the 
primary operation were not considered as recurrence. Patients developed contralateral 
disease following DCIS diagnosis were censored at the time of development of the 
contralateral cancer. Within a median follow up period of 103 months (range 6-331), 83 
cases (11%) developed a recurrence in the pure DCIS cohort compromising 30 DCIS 
(36%) and 53 IBC with or without DCIS (64%). Six recurrence events were developed 
after mastectomy and 11 events after management with breast conserving surgery 
(BCS) followed by adjuvant RT while the majority of the recurrences (n=66) occurred 
after BCS alone.   
Immunohistochemistry 
Tissue microarrays (TMAs) were prepared from DCIS cohorts. The TMA was constructed 
using a TMA GRAND MASTER 2.4-UG-EN MACHINE, using 1 mm punch sets. Cases with 
heterogeneous growth patterns or grades were sampled from all representative areas. 
For mixed cohort, a separate TMA from each component (DCIS and IBC) was 
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constructed. In addition, whole tissue sections from 12 cases compromising 8 pure DCIS 
and 4 DCIS-mixed cases were assessed to evaluate heterogeneity and the pattern of 
P4HA2 expression in malignant breast tissue and adjacent normal tissue. 
Primary antibody specificity for mouse monoclonal P4HA2 antibody [CL0351, ab211527, 
Abcam, UK] was validated using Western Blot on whole cell lysates of MCF7, MDA-
MB-231 and SKBR3 human breast cancer cell lines (obtained from the American Type 
Culture Collection; Rockville, MD, USA) as previously described 21-23. P4HA2 is expressed 
by epithelial tumour cells and specifically breast cancer cell lines as reported in Gilkes et 
al., Pan et al., and Xiong et al. 21-23, hence these cell lines were used. P4HA2 antibody 
was used at a dilution of 1:500 which showed a single specific band at the predicted size 
of 61 KDa (Figure 1A).  
Expression of P4HA2 protein in DCIS was assessed by immunohistochemistry (IHC) 
using the Novocastra Novolink TM Polymer Detection Systems kit (Code: RE7280-K, 
Leica, Biosystems, UK). TMA and full-face sections (4 µm) were stained with mouse 
monoclonal P4HA2 (dilution 1:100), incubated for 16 hours. Skin tissue was used as a 
positive control while a cerebral cortex tissue section was used as a negative control. 
For molecular characterisation of the DCIS cohort, immunohistochemical staining of 
oestrogen receptor (ER) progesterone receptor (PR) and HER2 was carried out on the 
TMA sections (4 µm). For ER and PR, sections were stained on the Ventana Benchmark® 
ULTRA system (Tucson, Arizona, USA) using Ventana anti-ER (SP1) Rabbit Monoclonal 
Primary Antibody and anti-PR (1E2) Rabbit Monoclonal Primary Antibody as per the 
recommended protocol. The primary antibody was applied for 16 minutes at 37°C 
followed by the OptiView HQ Linker for 8 minutes and the OptiView HRP Multimer for 8 
minutes. Cases with nuclear staining of more than 1% of the tumour cells were 
considered positive. HER2 status was assessed using IHC staining (1:400, DAKO, no 
antigen retrieval) with HercepTest scoring method as previously published 24,25. 
Chromogenic in situ Hybridisation (CISH) was used to assess the HER2 gene 
amplification to determine the final status of HER2 within equivocal cases. HER2 gene 
amplification was deemed positive where there were six or more signals per nucleus or 
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when clusters were identified in the tumour cell nuclei in more than 50% of tumour cells 
26. Moreover, as hypoxia is reported to be the key driver for P4HA2 upregulation 27, the 
pure DCIS cohort was stained and scored for hypoxia inducible factor 1 alpha (HIF-1a) 
[EPR16897, ab179483, Abcam, UK] as previously described 28. 
Scoring of P4HA2 expression  
Cytoplasmic expression of P4HA2 in tumour epithelial cells and the surrounding stromal 
fibroblasts was assessed. Semi-quantitative Histo-score (H-score) was applied for 
cytoplasmic expression of P4HA2 in epithelial cells (staining intensity was multiplied by 
the percentage of representative cells in the tissue for each intensity, producing a range 
of values between 0 and 300) 29. Cores containing <15% tumour epithelial cells and/or 
stroma were excluded from the scoring. All scored cores showed representative areas of 
specialised stroma 30 surrounding the malignant ducts. Cases with multiple cores 
(n=180) were scored and the average was used as a final score. Cytoplasmic expression 
of P4HA2 within the stromal fibroblasts was assessed as percentage of positive cells. 
Determination of the expression intensity within the scanty cytoplasm of the slender 
shaped fibroblasts was challenging; thus, staining intensity was not scored. For mixed 
cohort, we scored each component, DCIS and IBC, separately. The cases were scored by 
2 pathologists using multiheaded microscope. For dichotomisation of protein expression, 
cut-off points for either stromal or epithelial cells expression of P4HA2 were defined 
according to the conducted results from X-tile bioinformatics software (Yale University, 
version 3.6.1) based on LRFI in the pure DCIS cohort 31. High P4HA2 expression within 
tumour epithelial cells was considered when H-score was >40 while expression in >60% 
of the surrounding stromal fibroblasts was considered high expression.  
Analysis of P4HA2 mRNA expression in breast cancer: 
To emphasise the prognostic role of P4HA2 in breast cancer and given the lack of 
published data on the transcriptomic profiles of DCIS, the Molecular Taxonomy of Breast 
Cancer International Consortium (METABRIC) cohort 32, which comprises a large 
(n=1980) well characterised cohort of IBC with comprehensive molecular 
characterization was used. P4HA2 normalised gene expression (mRNA) was evaluated as 
a potential prognostic marker in the METABRIC dataset.  
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Statistical analysis 
Statistical analyses were performed using SPSS v21 (Chicago, IL, USA) for Windows. 
Student’s t test and analysis of variance (ANOVA) were used to correlate between P4HA2 
mRNA level as a continuous variable and other clinicopathological parameters in 
METABRIC data. Association with P4HA2 mRNA expression and breast cancer specific 
survival (BCSS) was done using uni- and multi-variate analysis models after 
dichotomisation of expression into high and low based on the median value. Spearman’s 
Rho test was used to correlate between P4HA2 expression with the tumour epithelial and 
stromal cells. Association between P4HA2 expression and clinicopathological parameters 
as well as RT in pure DCIS was performed using Chi-square, Mann Whitney and Kruskal-
Wallis tests. Wilcoxon signed rank test was used to compare the expression of P4HA2 
between DCIS component and invasive component within the DCIS-mixed cases. 
Univariate survival analysis against LRFI was carried out using log rank test and Kaplan 
Meier curves. Multivariate analysis and the interaction between P4HA2 expression and RT 
was analysed using Cox regression model. For all tests, a two-tailed p-value of less than 
0.05 was considered as statistically significant. 
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RESULTS 
Pattern of P4HA2 expression 
The evaluation of full-face tissue sections demonstrated a rather homogenous 
distribution of P4HA2 expression either within the tumour epithelial cells or the 
surrounding specialised stroma especially in cases with homogenous pattern and grade, 
indicating representability of TMAs to assess P4HA2 expression in our cohort. Adjacent 
normal breast terminal ducto-lobular units showed negative or faint cytoplasmic staining 
of P4HA2. Occasional myoepithelial and inflammatory cells in a few cores were also 
stained. When present, P4HA2 was expressed in the cytoplasm of the epithelial tumour 
cells and surrounding fibroblasts.  
After excluding of uninformative cores (they were randomly excluded due to loss of the 
cores during TMA construction or antigen retrieval, folded tissue during processing or 
cores containing <15% tumour cells), the final number of cases suitable for scoring was 
481 in pure DCIS and 196 in DCIS-mixed cohorts. P4HA2 expression showed a unimodal 
distribution. The median H-score for P4HA2 expression was 40 in pure DCIS (range 
0-250), 50 in the DCIS component of mixed cases (range 0-280), and 40 in IBC 
component of the latter (range 0-280). For stromal expression, the median percentage 
of positive stromal cells was 30% in pure DCIS (range 0-95), 55% in the DCIS 
component of mixed cases (range 0-95) and 80% in the invasive component of the latter 
(range 0-95). Within the pure DCIS cohort, high P4HA2 expression was observed in 
247/481 (51.4%) and 121/481 (25.2%) in tumour epithelial and surrounding stromal 
cells; respectively. There was a positive linear correlation between expression of P4HA2 
within the epithelial cells and surrounding fibroblasts (r=0.426, p<0.0001, Spearman’s 
correlation).  
The proportion of cases with high P4HA2 was greater in DCIS-mixed than pure DCIS, 
both within the tumour epithelial cells (54% of pure DCIS cases vs. 64% of DCIS mixed 
with IBC, χ2=8.6, p=0.003) and stromal cells (25% for pure DCIS vs. 50% of DCIS 
mixed with invasion, χ2=39.3, p<0.0001). Supporting this, similar observations results 
were observed when the data had been analysed in a continuous scale (p=0.006 and 
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p<0.0001, for tumour epithelial cells and stromal cells, respectively). Although there was 
no statistically significant difference between P4HA2 expression within the tumour 
epithelial cells of DCIS component and invasive component of DCIS-mixed cases 
(p=0.188), its expression within the stromal fibroblasts surrounding the invasive 
component was higher than those surrounding the DCIS component (p<0.0001). 
Different patterns of P4HA2 expression within the pure DCIS and DCIS-mixed cohorts 
are shown in Figure 1 (B-F). Supplementary Figure 1 shows some examples of P4HA2 
expression around 40 H score.   
Significance of P4HA2 expression in pure DCIS 
High expression of P4HA2 within the malignant epithelial cells and/or surrounding 
stromal fibroblasts in the pure DCIS was associated with various clinicopathological 
parameters characteristic of high risk DCIS (Table 1) including younger age at diagnosis, 
DCIS presented symptomatically, high nuclear grade, presence of comedo necrosis, ER 
negativity, PR negativity, HER2 positivity, and triple negative DCIS. Also, there was a 
positive association between high P4HA2 expression either within tumour epithelial cells 
or stromal cells and high HIF-1a expression. The majority of patients receiving post-
operative adjuvant RT showed high P4HA2 expression as well. Analysis of continuous 
data of P4HA2 expression scores showed comparable results (Supplementary Table 2).   
To validate the prognostic value of P4HA2 in IBC, the METABRIC cohort 32 was used to 
assess the levels of P4HA2 mRNA and correlate its expression with the clinicopathological 
variables and outcome. We considered mRNA expression data to be valid for comparison, 
as The Cancer Genome Atlas data (cBio, Provisional breast cancer data set, obtained 
February 2018) shows that P4HA2 mRNA expression by RNAseq and protein expression 
by mass spectrometry in 70 IBC were significantly positively correlated (p<0.0001, 
Spearman r=0.48). Analysis using the Breast Cancer Gene-Expression Miner v4.1(bc-
GenExMiner v4.1) database showed that high P4HA2 mRNA is associated with higher 
metastatic relapse and/or death (p<0.0001). Similar associations with aggressive 
clinico-pathologic features were observed when evaluating P4HA2 mRNA level in the 
invasive tumours of the METABRIC series (n=1980), for example with high tumour grade 
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(p=0.03), lymph node metastasis (p=0.028), ER negativity (p=0.0001), HER2 positivity 
(p<0.0001) in addition to shorter breast cancer specific survival (BCSS) (HR=1.3, 
95%CI=1.1-1.6, p=0.002). Multivariate analysis showed that higher P4HA2 mRNA level 
was independently associated with shorter BCSS (Supplementary Tables 3, 4 and 
Supplementary Figure 2).   
Outcome analysis in pure DCIS cohort  
High P4HA2 expression within tumour epithelial cells was associated with shorter LRFI in 
the whole cohort of pure DCIS (HR=2.3, 95%CI=1.3-4.1; p=0.003, Figure 2) and in the 
luminal ER-positive/HER2-negative subgroup (HR=3.3, 95%CI=1.1-5.2; p=0.001). 
Association with shorter LRFI was observed in patients treated with BCS without 
adjuvant radiotherapy (RT) (HR=3.6, 95%CI=1.9-7.1; p<0.0001), however; the 
significant association with poor outcome was not maintained in patients treated with 
either mastectomy or BCS followed by adjuvant RT (HR=0.9, 95%CI=0.2-4.8; p=0.9 
and HR=1.8, 95%CI=0.3-9.1; p=0.5, respectively). Interestingly, there was an 
association between high P4HA2 expression and ipsilateral local recurrence as invasive 
disease in patients treated with BCS without post-operative adjuvant RT (HR=2.4, 
95%CI=1.1-5.2; p=0.03) but this associated lost its significance in patients who were 
offered adjuvant RT (Figures 2 and 3).  
To further evaluate the impact of P4HA2 on the outcome in the context of adjuvant RT 
response, the cohort of pure DCIS treated with BCS was stratified based on P4HA2 
expression. In the high P4HA2 expression group, there was a statistically significant 
association between adjuvant RT and longer LRFI (HR=0.3, 95%CI=0.1-0.8; p=0.01). In 
the low P4HA2 expression cohort, this association was lost (HR=0.6, 95%CI=0.1-2.8; 
p=0.5) (Figure 4). The interaction between the combined RT and P4HA2 expression and 
outcome in the cox regression model showed similar results, whereas RT*P4HA2 
expression showed a significant association with outcome (p=0.01, HR=3.4, 
95%CI=1.3-8.7).  
Stromal expression of P4HA2 did not show any significant association with tumour 
recurrence. Forest plots illustrating the association between different clinicopathological 
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parameters and ipsilateral local tumour recurrence are shown in Supplementary Figure 
3a (all recurrences either DCIS or IBC) and Supplementary Figure 3b (invasive 
recurrences only). 
Multivariate survival analysis showed that tumour expression of P4HA2 is a poor 
prognostic factor for tumour recurrence in patients treated with BCS independent of 
known other determinants of high risk DCIS including patient age, nuclear grade, tumour 
size, presence of comedo necrosis and RT in the model (HR=2.3, 95% CI=1.3-4.4; 
p=0.007) (Table 2). 
Furthermore, when patients treated with BCS were stratified based on clinicopathological 
variables into high/intermediate (higher) risk and low risk groups, using the Van Nuys 
Prognostic Index 33, the ipsilateral local recurrence rate was comparable (12% and 10% 
for the higher and low risk groups; respectively). When P4HA2 expression was 
incorporated, the recurrence rate for the higher risk/high P4HA2 group (35% of the final 
cohort; i.e. 168/481 patients) was 16% but only 8% for the higher risk/low P4HA2 
group. Interestingly, the low risk/high P4HA2 group (15% of the final cohort) showed a 
13% ipsilateral local recurrence rate, while the low risk/low P4HA2 group had a 
recurrence rate of 6%. Further categorisation, in context of post-operative RT, showed 
that the recurrence rate in higher risk/high P4HA2 group with no RT is 25% compared to 
6% for higher risk/high P4HA2 patients who received RT. Similarly, there was 19% 
ipsilateral local recurrence rate in low risk/high P4HA2 patients who did not receive RT 
compared to 5% in patients who offered adjuvant RT. The recurrence rate in low risk/low 
P4HA2 group with or without post-operative RT was comparable (3% and 4%, 
respectively). These results indicate that P4HA2 is a promising marker for better DCIS 
risk stratification and hence better personalised management.  
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Discussion 
Despite breakthroughs in various molecular techniques, predictors for DCIS 
aggressiveness remain elusive. Lack of robust prognostic markers is due to lack of 
adequately powered and methodologically sound studies (case-control, unbiased, 
comparison between DCIS that recur as invasive disease versus those do not). DCIS 
progression is a complex process with interaction between tumour cells and 
microenvironment. An explanation of disease progression based exclusively on intrinsic 
tumour cell factors is insufficient, as there is group of low grade DCIS with indolent 
appearance and low proliferation index that yet carries progression potential to IBC 34. In 
contrast, a considerable proportion of high-grade proliferating lesions remain as DCIS 
without progression. Laser-capture microdissection and microarray analysis show that 
whereas thousands of genes are differentially expressed in the epithelium during the 
transition from normal to DCIS, the majority of genes consistently showing differential 
expression from DCIS to IBC are associated with the stromal microenvironment, 
highlighting its profound importance in the development of IBC 12,35-38. It was reported 
that changes in the breast tumour microenvironment are often observed as early as the 
DCIS stage or even earlier, where hyperactive mitogenic signalling in epithelial cells 
results in secretion of many chemokines which modulate the surrounding tissues in a 
paracrine-like action 39,40. In turn, the stromal and epithelial cells participate in reciprocal 
and paracrine-acting signalling loops, which then remodel and condition the ECM and 
promote tumour cell proliferation, maintenance and invasion 12,14,41,42.  
P4HA2 is one of the key regulator enzymes for collagen biosynthesis, stabilisation, ECM 
remodelling and stiffness 18 and has been reported to associate with poor outcome in 
many malignant tumours 19,20,23. Using the METABRIC cohort for robust molecular data in 
a large number of IBC showed associations between aggressive behaviour of IBC and 
higher levels of P4HA2 mRNA. This observation supports our hypothesis that P4HA2 is a 
promising candidate marker for evaluation as studies to decipher its role in DCIS 
behaviour and its association with disease progression have been lacking.  
In our study, we evaluated the pattern of P4HA2 expression either within tumour 
epithelial cells or surrounding fibroblasts in a large annotated cohort of DCIS with long 
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term follow up data. This is the first report of IHC staining for P4HA2 in any human 
breast tumour cohort to our knowledge. High expression of P4HA2 was associated with 
other determinants of high risk DCIS and poor outcome. These associations give insight 
for the potential role of P4HA2 in DCIS behaviour through its action in enhancing stromal 
stiffness and collagen deposition/alignment, which in turn might help in tumour 
aggressiveness 43. Supporting this idea, our results showed that P4HA2 expression is 
higher in DCIS co-existing with invasive carcinoma than pure DCIS, and much higher in 
the stromal fibroblasts surrounding the invasive component. These findings are further 
supported by gene expression profiles that showed P4HA2 mRNA level is higher in IBC 
than DCIS 22,23. Stromal fibroblasts as well as tumour cells can produce P4HA2 and affect 
the surrounding ECM 21. Our data showing strong tumour epithelial cell expression is 
entirely consistent with this report. 
Importantly, our data showed association of higher P4HA2 expression with invasive 
recurrence. In concordance with our findings, thickening and linearisation of collagen 
fibres are often found in areas of active tissue invasion, suggesting their active role in 
facilitating cancer progression 17. Indeed, studies using live imaging have shown that 
cancer cells migrate rapidly in areas enriched in collagen 44. Gilkes et al., reported that 
cancer cell invasion usually occurs with oriented collagen fibres at the tumour-stromal 
interface, and aligned collagen fibres can facilitate cell migration and invasion 21. 
Moreover, in xenograft models a significant amount of aligned collagen fibres is detected 
in the tumours’ invasion margins in a control group compared to the P4HA2-silenced 
group 23. Taken together, DCIS with high P4HA2 expression may have a 
microenvironment supportive of tumour growth and therefore need to be managed 
properly to avoid progression or recurrence. Our study shows that expression of P4HA2 
in the tumour, but not stromal expression, is associated with recurrence a finding that 
might reflect the potential epithelial cell-intrinsic role of early stage tumours in ECM 
remodelling that facilitates tumour progression and the dual role of tumour and stromal 
cells in progression and aggressiveness of advanced tumours. The latter interaction is 
supported by the dramatic increase of P4HA2 expression in stromal cells surrounding the 
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invasive component compared to those surrounding the DCIS component in mixed cases 
or those surrounding pure DCIS. However, further functional studies are highly 
recommended to understand the underlying mechanisms of P4HA2 expression in 
carcinogenesis and tumour progression either from the tumour cells or the surrounding 
stroma.  
Interestingly, our results show that high P4HA2 expression is not associated with 
recurrence in patients treated with postoperative radiotherapy. Moreover, postoperative 
RT is associated with longer LRFI in patients with high P4HA2 than those with low P4HA2 
expression. Taken together, P4HA2 is not only a marker to identify high-risk patients who 
need proper treatment with surgery followed by radiation, but also suggest that adjuvant 
RT provides more benefit in DCIS expressing high levels of P4HA2, which needs further 
investigation to understand the underlying mechanisms.  
Nonetheless, multivariate analysis shows that only RT and P4HA2 expression were 
significant prognostic factors, suggesting P4HA2 may be a more powerful marker of high 
risk than conventional features. Moreover, in our cohort, using the conventional 
clinicopathological features and the previously described Van Nuys Prognostic Index 33 
could not provide a proper DCIS risk stratification in term of disease recurrence, which 
supports the contention that more robust criteria for DCIS risk determination is required. 
Incorporation of P4HA2 with the other clinicopathological factors provided a better 
identification of different risk groups. These findings indicate that P4HA2 is a promising 
marker for better definition of high risk DCIS as well as identification of a group of 
patients with lower risk where radiotherapy could be omitted.   
Although the exact mechanism of how P4HA2 overexpression and subsequent ECM 
remodelling helps in tumour progression is unclear, there are many hints from existing 
data. Deregulation of ECM dynamics can facilitate cellular dedifferentiation and cancer 
stem cell expansion 45,46. Additionally, it disrupts tissue polarity and promotes cellular 
motility and tissue invasion 47. As a result, epithelial cells are directly affected by 
deregulated ECM dynamics, leading to cellular transformation and metastasis 45,47-49. 
Collagen fibre alignment plays a critical role in directing the migration of tumour cells in 
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vivo 50. Moreover, increased stromal stiffness in breast cancer facilitates integrin 
clustering to promote focal adhesions between tumour cells and surrounding stroma, 
which drive invasion 51. Also, it has been shown in xenograft studies that P4HA2 
regulates tumour growth. Silencing of P4HA2 expression or treatment with a P4HA 
inhibitor significantly inhibited cell proliferation and suppressed aggressive phenotypes of 
breast cancer cells in 3D culture, accompanied by reduced deposition of collagen I and 
IV 23.  
A key driver of P4HA2 and other ECM remodelling proteins is hypoxia and related factors, 
mainly HIF-1a 27, supporting our finding that high P4HA2 expression is associated with 
higher levels of HIF-1a. P4HA2 has been reported to co-localise with HIF-1α in peri-
necrotic, i.e. hypoxic, areas within tumours 27,52. The hypoxia pathway has a complex 
role in tumour progression through enhancing angiogenesis, tumour proliferation, 
secretion of growth factors and other proteolytic enzymes 52. Therefore, P4HA2 
overexpression might be a consequence of hypoxia related changes. In addition, hypoxia 
is associated with overexpression of lysyl oxidases, proteins known to promote cell 
invasion by increasing tissue tension and ECM rigidity 23. These results indicate that the 
ECM microenvironment remodelled by cancer cells is critical for cancer progression. 
Conclusion  
ECM remodelling plays a crucial role in tumour progression. P4HA2 might have a 
potential role in DCIS aggressiveness through its regulatory role in collagen biosynthesis 
and enhancing ECM stiffness. Hypoxia and related factors could be the key drivers of 
such pathway. More functional studies to decipher the role of P4HA2 and its mechanism 
of action in DCIS behaviour are warranted. P4HA2 may also be a valuable prognostic 
indicator, particularly in the ER+/HER2- luminal tumours for which a biomarker that 
could prevent over treatment, i.e. avoid radiotherapy, is urgently required.  
Limitations of the study 
This study has been carried out on TMA sections, which might underestimate the role of 
tumour heterogeneity. However, all cases in our cohort were histologically reviewed 
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before TMA construction and used multiple cores for cases with heterogeneous grades or 
morphological patterns. Additionally, staining of some full-face sections was performed 
to assess the pattern of protein distribution and no obvious staining heterogeneity was 
observed. Lack of data for some potential confounders such as family history of breast 
cancer or obesity is also a limitation. Our cohort did not include any patients treated with 
endocrine therapy. Finally, the current study addressed the prognostic significance of 
P4HA2 in DCIS, but more functional mechanistic studies are highly recommended to 
decipher its actual role in carcinogenesis and DCIS progression as well as its interaction 
with radiotherapy. Evaluation the biological and prognostic roles of P4HA2 in larger 
validation cohorts of different DCIS subgroups, for instance, high risk, low risk DCIS, 
patients treated with BCS and adjuvant radiotherapy with long term follow up period 
would provide better understanding for such interaction. 
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Figures Legends: 
Figure 1: Anti-P4HA2 antibody validation and patterns of protein expression. A) Western 
blot of mouse monoclonal anti-P4HA2 antibody showing a single specific band (upper red 
band) at expected molecular weight (61 kDa) in MCF-7, MDA-MB-231 and SKBR3 cell 
lysates. The lower green band represents the beta-actin (positive control) at 42kDa 
molecular weight, B) Normal breast duct (x20) shows faint cytoplasmic staining of 
P4HA2 in the normal epithelial cells. Occasional faint staining in the myoepithelial cells is 
also noticed, C) Negative P4HA2 expression (x40) in a pure DCIS case; D) strong 
expression of P4HA2 in tumour cells and surrounding fibroblasts (x20) in a pure DCIS 
case.  E and F) Expression of P4HA2 in a mixed case (x40) showing almost the same 
intensity within the tumour cells of DCIS component (E) and invasive component (F) 
while expression within the surrounding stromal fibroblasts is higher in invasive 
component (F). 
Figure 2: Kaplan Meier curves show that high expression of P4HA2 within the tumour 
epithelial cells is associated with shorter ipsilateral local recurrence free survival (LRFS) 
in the whole series (A), and in luminal/HER2- subgroup (B). High expression also showed 
an association with shorter LRFI in patients treated with breast conserving surgery (BCS) 
without adjuvant radiotherapy (C) but not in patients treated with breast conserving 
surgery followed by adjuvant radiotherapy (D). 
Figure 3: Kaplan Meier curve shows association between high P4HA2 expression within 
the DCIS malignant epithelial cells and ipsilateral local recurrences as invasive carcinoma 
in patients treated with breast conserving surgery alone (BCS). 
Figure 4: Kaplan Meier curves show association between post-operative adjuvant 
radiotherapy (RT) and recurrence within low and high P4HA2 expression groups; (A) in 
low P4HA2 expression group, (B) longer LRFI in patients treated with RT following breast 
conserving surgery (BCS) in high P4HA2 expression group. 
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Table 1: Correlation between P4HA2 expression in DCIS malignant epithelial cells and 
stromal fibroblasts with different clinicopathological parameters in the pure DCIS cohort  
significant p values are in bold  
P4HA2; prolyl-4-hydroxlase alpha subunit 2, DCIS; ductal carcinoma in situ, HER2; Human epidermal growth 
factor receptor 2, BCS; breast conserving surgery, IBC; invasive breast cancer, HIF1-a; hypoxia inducible factor 
1 alpha.   
*HER2 final status is achieved using combination of IHC and chromogenic in situ hybridisation (CISH). 
**For patients treated with breast conserving surgery. 
***Including the cases in both cohorts; i.e. pure DCIS cohort (n=481) + DCIS-mixed cohort (n=196).   
Parameters
P4HA2 expression in 
tumour epithelial cells
χ2 
(p-value)
P4HA2 expression in stromal 
fibroblasts
χ2 
(p-value)Low 
(N=234) 
N. (%)
High 
(N=247) 
N. (%)
Low 
(N=360) 
N. (%)
High 
(n=121) 
N. (%)
Patient Age 
   ≤45 years 
   >45 years
18 (8) 
216 (92)
40 (16) 
207 (84)
8.2 
(0.004)
38 (11) 
322 (89)
20 (17) 
101 (83)
3.0 
(0.081)
DCIS Presentation  
   Screening 
   Symptomatic
126 (54) 
108 (46)
112 (45) 
135 (55)
3.5 
(0.062)
189 (53) 
171 (47)
49 (40) 
72 (60)
5.2 
(0.020)
DCIS Size 
   ≤20mm 
   >20mm
103 (44) 
130 (56)
101 (41) 
144 (59)
0.4 
(0.510)
158 (44) 
200 (56)
46 (38) 
74 (62)
1.2 
(0.266)
DCIS Nuclear Grade 
   Low 
   Moderate 
   High
51 (22) 
73 (31) 
110 (47)
10 (4) 
52 (21) 
185 (75)
49.4 
(<0.0001)
52 (14) 
98 (27) 
210 (59)
9 (7) 
27 (22) 
85 (71)
6.4 
(0.04)
Comedo necrosis  
   Yes 
   No
130 (56) 
104 (44)
191 (77) 
56 (23)
25.6 
(<0.0001)
226 (63) 
134 (37)
95 (79) 
26 (21)
10.1 
(0.001)
Estrogen receptor (ER)  
   Negative 
   Positive
24 (11) 
190 (89)
93 (41) 
132 (59)
50.9 
(<0.0001)
75 (23) 
256 (77)
42 (39) 
66 (61)
10.9 
(0.001)
Progesterone receptor 
(PR) 
   Negative 
   Positive
65 (30) 
149 (70)
121 (54) 
103 (46) 25.0 (<0.0001)
127 (38) 
203 (62)
59 (55) 
49 (45) 8.7 (0.003)
HER2 status * 
   Negative 
   Positive
164 (81) 
38 (19)
156 (69) 
70 (31)
8.4 
(0.004)
245 (77) 
75 (23)
75 (69) 
33 (31)
2.2 
(0.141)
Surgical Management 
   Mastectomy 
   BCS 
130 (56) 
104 (44)
142 (58) 
105 (42)
0.2 
(0.669) 204 (57) 156 (43)
68 (56) 
53 (44)
0.1 
(0.928)
Radiotherapy (RT) **  
   Yes  
   No
29 (28) 
75 (72)
42 (40) 
63 (60)
3.5 
(0.04) 43 (28) 113 (72)
28 (53) 
25 (47)
11.3 
(0.001)
Molecular classes 
   Luminal/HER2– 
   Luminal/HER2+ 
   ER-/HER2+ 
   Triple negative
147 (76) 
24 (12) 
11 (6) 
11 (6)
98 (47) 
28 (13) 
36 (17) 
48 (23)
45.9 
(<0.0001)
198 (65) 
37 (12) 
33 (11) 
37 (12)
47 (48) 
15 (15) 
14 (14) 
22 (23)
10.2 
(0.017)
HIF1-a expression 
   High 
   Low 
24 (15) 
141 (85)
132 (66) 
68 (34)
18.1 
(<0.0001)
58 (21) 
213 (79)
34 (36) 
60 (64)
8.1 
(0.004)
I p s i l a t e r a l l o c a l 
recurrence  
   Yes 
   No 
17 (7) 
217 (93)
39 (16) 
208 (84)
8.5 
(0.004)
47 (13) 
313 (87)
9 (8) 
112 (92)
2.8 
(0.100)
DCIS Type*** 
   Pure DCIS 
   DCIS with IBC
234 (77) 
71 (23)
247 (66) 
125 (34)
8.6 
(0.003)
360 (79) 
98 (21)
121 (55) 
98 (45)
39.3 
(<0.0001)
!  23
Table 2: Multivariate survival analysis (Cox regression model) of variables predicting 
outcome in terms of ipsilateral local recurrence in patients treated by breast conserving 
surgery in pure DCIS cohort  
significant p values are in bold  
P4HA2; prolyl-4-hydroxlase alpha subunit 2, DCIS; ductal carcinoma in situ. 
Parameters  Hazard ratio 
(HR)
95.0% confidence 
interval (CI)
Significance 
p-value
Lower Upper
High P4HA2 expression 3.1 1.5 6.3 0.002
Patient Age 0.6 0.2 1.5 0.286
DCIS presentation 1.5 0.7 2.9 0.278
DCIS size 1.3 0.7 2.5 0.437
DCIS nuclear Grade 1.3 0.7 2.3 0.373
Comedo necrosis 1.1 0.5 2.1 0.895
Molecular classes 0.8 0.5 1.1 0.170
Radiotherapy 0.3 0.1 0.8 0.015
Margin status 0.8 0.5 1.4 0.510
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Supplementary Table 1: Clinicopathological parameters of the pure DCIS cohort*. The 
whole primary cohort including 776 cases and the final cohort including 481 cases after 
P4HA2 scoring are shown.   
Parameters
Whole cohort 
N=776 cases 
N (%)
Final cohort 
N=481 cases 
N (%)
Mean patient age (years ± SD) 57 ± 9 (range 28-86) 57 ± 10 (range 28-86)
Mean DCIS size (mm ± SD) 30 ± 26 (range 1-180) 35 ± 28 (range 1-180)
Patient age 
   ≤45 years 
   >45 years
78 (10) 
698 (90)
58 (11) 
423 (89)
DCIS Presentation 
   Screening 
   Symptomatic
421 (54) 
355 (46)
238 (50) 
243 (50)
DCIS Size 
   ≤20mm 
   >20mm 
   N/A
382 (49) 
386 (50) 
7 (1)
204 (42) 
274 (57) 
3 (1)
DCIS Nuclear Grade 
   Low 
   Moderate 
   High
102 (13) 
192 (25) 
482 (62)
61 (13) 
125 (26) 
295 (61)
Comedo necrosis 
   Yes 
   No
497 (64)  
279 (36)
321 (67) 
160 (33)
Surgical Management 
   Breast conserving surgery (BCS)  
   Mastectomy
375 (48) 
401 (52)
209 (44) 
272 (56)
Final Margin Status** 
   Positive (Tumour on ink) 
   <2mm 
   ≥2mm 
   Unknown
9 (2) 
11 (3) 
326 (87) 
29 (8)
6 (3) 
8 (4) 
179 (86) 
16 (7)
Radiotherapy (RT)** 
   No 
   Yes
265 (71) 
110 (29)
138 (66) 
71 (34)
Estrogen receptor (ER) status  
   Negative 
   Positive 
   N/A
148 (19) 
439 (57) 
189 (24)
117 (24) 
322 (67) 
42 (9)
Progesterone receptor (PR) status 
   Negative 
   Positive 
   N/A
248 (32) 
336 (43) 
192 (25)
186 (39) 
252 (52) 
43 (9)
HER2 status***  
   Negative 
   Positive 
   N/A
496 (64) 
133 (17) 
147 (19)
320 (67) 
108 (22) 
53 (11)
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P4HA2; prolyl-4-hydroxlase alpha subunit 2, DCIS; ductal carcinoma in situ, HER2; Human epidermal growth 
factor receptor 2, BCS; breast conserving surgery, HIF1-a; hypoxia inducible factor 1 alpha.   
*Mixed DCIS-IBC cohort included 239 patients with mean age 53±9 years, 155 cases (64%) had extensive 
DCIS, 167 cases (69%) were of high nuclear grade and comedo type necrosis was seen in 175 cases (73%). 
**For patients treated with breast conserving surgery  
***HER2 final status is achieved using combination of IHC and chromogenic in situ hybridisation (CISH). 
Molecular classes 
   Luminal/HER2– 
   Luminal/HER2+ 
   ER-/HER2+ 
   Triple negative 
   N/A
335 (43) 
60 (8) 
51 (7) 
80 (10) 
250 (32)
245 (51) 
52 (11) 
47 (10) 
59 (12) 
78 (16)
HIF1-α expression 
   High 
   Low 
   N/A
105 (14) 
364 (47) 
307 (39)
92 (19) 
273 (57) 
116 (24)
Recurrence 
   DCIS recurrence 
   Invasive recurrence
30 (36) 
53 (64)
22 (39) 
34 (61)
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Supplementary Table 2: Correlation between P4HA2 expression in DCIS malignant 
epithelial cells and stromal fibroblasts with different clinicopathological parameters in the 
pure DCIS cohort using continuous data.  
significant p values are in bold  
P4HA2; prolyl-4-hydroxlase alpha subunit 2, DCIS; ductal carcinoma in situ, HER2; Human epidermal growth 
factor receptor 2, BCS; breast conserving surgery, IBC; invasive breast cancer, HIF1-a; hypoxia inducible factor 
1 alpha.   
*HER2 final status is achieved using combination of IHC and chromogenic in situ hybridisation (CISH). 
**For patients treated with breast conserving surgery.  
Parameters Number of 
cases
P4HA2 expression in tumour 
epithelial cells (H-score)
P 4 H A 2 e x p r e s s i o n i n 
stromal fibroblasts (%)
Mean Rank p-value Mean Rank p-value
Patient Age 
   ≤45 years 
   >45 years
58 
423
286.0 
234.8
 0.008 288.3 
234.5
0.005
DCIS Presentation  
   Screening 
   Symptomatic
238 
243
227.8 
253.9
0.038 222.1 
259.5
0.003
DCIS Size 
   ≤20mm 
   >20mm
204 
274
227.5 
248.5
0.098 228.7 
247.5
0.136
DCIS Nuclear Grade 
   Low 
   Moderate 
   High
61 
125 
295
145.1 
217.9 
270.6
 <0.0001
201.5 
219.5 
258.3
0.002
Comedo necrosis  
   Yes 
   No
321 
160
263.1 
196.7  <0.0001
258.3 
206.2  <0.0001
Estrogen receptor (ER)  
   Negative 
   Positive
117 
322
290.2 
194.5
 <0.0001 263.3 
204.3
 <0.0001
Progesterone Receptor (PR) 
   Negative 
   Positive
186 
252
258.2 
190.9
<0.0001 248.8 
197.8
<0.0001
HER2 status* 
   Negative 
   Positive
320 
108
200.9 
254.6
 <0.0001 205.7 
240.5
0.011
Radiotherapy (RT) **  
   Yes  
   NO
71 
138
123.3 
95.6
0.002 125.5 
94.4
0.0003
Treatment Group  
   Mastectomy 
   BCS 
272 
209
249.3 
230.2
0.134 242.9 
238.2
0.725
Molecular classes 
   Luminal/HER2– 
   Luminal/HER2+ 
   ER-/HER2+ 
   Triple negative
245 
52 
47 
59
170.8 
219.2 
268.9 
263.2
 <0.0001
183.7 
209.6 
243.8 
238.4
 <0.0001
HIF1-a expression 
   High 
   Low 
92 
273
233.4 
166.0  <0.0001
223.3 
169.4  <0.0001
DCIS Type 
   Pure DCIS 
   DCIS with IBC
481 
196
325.8 
371.4
0.006 302.3 
429.0
 <0.0001
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Supplementary Table 3: Correlation between P4HA2 mRNA level and the 
clinicopathologic parameters in the METABRIC series of invasive breast cancers 
(n=1980). 
significant p values are in bold  
 METABRIC:   Molecular Taxonomy of Breast Cancer International Consortium 
Parameter Number o f 
cases
Mean P4HA2 
mRNA level
p-value
Patient Age 
   <50 years 
   ≥50 years
383 
1556
8.3 
8.3
0.336
Tumour Size 
   ≤20 mm 
   >20 mm
622 
1331
8.3 
8.3
0.535
Histologic Grade 
   1 
   2  
   3
170 
770 
952
8.2 
8.2 
8.3
0.034
Lymph node metastasis  
   Negative 
   Positive
1035 
938
8.2 
8.3
0.028
Oestrogen Receptor (ER) Status 
   Positive 
   Negative
1506 
474
8.2 
8.4
0.0001
HER2 Status 
   Negative 
   Positive
1733 
247
8.2 
8.5
<0.0001
PAM50 molecular classes 
   Luminal A 
   Luminal B 
   Basal-like 
   HER2 enriched 
   Normal like
718 
488 
329 
240 
199
8.2 
8.3 
8.3 
8.4 
8.2
0.005
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Supplementary Table 4: Multivariate survival analysis (Cox regression model) of 
variables predicting breast cancer specific survival in METABRIC data.  
significant p values are in bold  
METABRIC:   Molecular Taxonomy of Breast Cancer International Consortium 
Supplementary Figures  
Parameters Hazard ratio 
(HR)
95.0% confidence 
interval (CI)
Significance 
p-value
Lower Upper
High P4HA2 mRNA expression  1.3 1.1 1.5 0.007
Patient Age 1.0 0.8 1.3 0.994
Tumour Grade 1.3 1.1 1.6 0.004
Tumour Stage 2.1      1.7 2.6 0.0001
Lymph node metastasis 1.4 1.1 1.9 0.010
Molecular classes 1.1 1.1 1.2 0.028
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Supplementary Figure 1: Examples of H score around 40 for P4HA2 expression in 
DCIS tumour epithelial cells.   
#
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Supplementary Figure 2: Association between P4HA2 mRNA level and outcome in 
terms of breast cancer specific survival (BCSS) in the METABRIC series. The cohort was 
split into high and low mRNA expression based on the median (=8.28).  
&
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Supplementary Figure 3: Forest plots showing the univariate analysis results of 
association between different clinicopathological parameters and ipsilateral tumour 
recurrence for patients treated with breast conserving surgery in pure DCIS cohort; 
A) all recurrences whether DCIS or invasive and B) for invasive recurrences only. High 
expression of P4HA2 in tumour epithelial cells is associated with higher recurrence risk in 
both groups.
&
&
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